Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
The following slide deck was published by Ipsen S.A. in conjunction with their 2022 Q2 earnings call. For further details see: Ipsen S.A. 2022 Q2 - Results - Earnings Call Presentation
Ipsen S.A. press release ( OTCPK:IPSEY ): 1H Non-GAAP EPS of €4.74. Revenue of €1.43B (+15.3% Y/Y). For further details see: Ipsen S.A. Non-GAAP EPS of €4.74, revenue of €1.43B
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022: H1 2022 financial results Strong sales growth of 10.5% at CER 1 (15.2% as reported) Core operatin...
Epizyme’s approved drug Tazverik revenue disappointed investors. Ipsen will pay $1.45 per share for Epizyme stock, plus a CVR. Any speculation at this point is about the value of the CVR. Epizyme ( EPZM ) graduated to being a commercial pharmaceutical company ...
The U.S. Food and Drug Administration (FDA) granted priority review to Ipsen's (OTCPK:IPSEY) (OTCPK:IPSEF) resubmitted new drug application (NDA) seeking approval of oral drug palovarotene to treat patients with fibrodysplasia ossificans progressiva (FOP). FOP is a rare genetic disorder ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the treatment of patients with fibrodysplasia ossifica...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...
France's Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) is acquiring Cambridge, Mass.-based cancer drug maker Epizyme (NASDAQ:EPZM) for $247M plus contingent value right (CVR). Ipsen will begin an all-cash tender offer to acquire all outstanding shares of Epizyme (EPZM) for $1.45/share plus a CV...
Transaction focused on lead asset Tazverik ® (tazemetostat), a first-in-class EZH2 a inhibitor approved in the U.S. Acquisition to bolster Ipsen’s growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to...
Transaction focused on lead asset Tazverik ® (tazemetostat), a first-in-class EZH2 a inhibitor approved in the U.S. Acquisition to bolster Ipsen’s growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...